Literature DB >> 12672169

Use of paroxetine for the treatment of depression and anxiety disorders in the elderly: a review.

Michel Bourin1.   

Abstract

Paroxetine is a potent selective serotonin reuptake inhibitor (SSRI) with indications for the treatment of depression, obsessive- compulsive disorder, panic disorder and social phobia. It is also used in the treatment of generalized anxiety disorder, post-traumatic stress disorder, premenstrual dysphoric disorder and chronic headache. There is wide interindividual variation in the pharmacokinetics of paroxetine in adults as well as in the elderly with higher plasma concentrations and slower elimination noted in the latter. Elimination is also reduced in severe renal and hepatic impairment, however, serious adverse events are extremely rare even in overdose. A Pub Med search was used to collect information on the efficacy and tolerability in elderly patients. There are few studies of depression in the elderly and only one study in the old-old. In anxiety disorders including general anxiety disorder, panic disorder, obsessive-compulsive disorder and social anxiety, there are no studies at all in the elderly. However, the safety of the drug allows its prescription in the elderly. In summary, paroxetine is well tolerated in the treatment of depression in those between the ages of 65 and 75, although few studies have examined its use in those of 75 and older. Copyright 2002 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12672169     DOI: 10.1002/hup.467

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  5 in total

Review 1.  Late-life anxiety disorders: a review.

Authors:  Josien Schuurmans; Anton van Balkom
Journal:  Curr Psychiatry Rep       Date:  2011-08       Impact factor: 5.285

Review 2.  Overuse of antidepressant drugs for the treatment of depression.

Authors:  Jon Jureidini; Anne Tonkin
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

3.  Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice.

Authors:  Rhonda L Nelson; Zhihong Guo; Veerendra Madala Halagappa; Michelle Pearson; Audrey J Gray; Yasuji Matsuoka; Martin Brown; Bronwen Martin; Titilola Iyun; Stuart Maudsley; Robert F Clark; Mark P Mattson
Journal:  Exp Neurol       Date:  2007-02-13       Impact factor: 5.330

4.  The Anti-inflammatory Compound Candesartan Cilexetil Improves Neurological Outcomes in a Mouse Model of Neonatal Hypoxia.

Authors:  Sean Quinlan; Paula Merino-Serrais; Alessandra Di Grande; Heiko Dussmann; Jochen H M Prehn; Tríona Ní Chonghaile; David C Henshall; Eva M Jimenez-Mateos
Journal:  Front Immunol       Date:  2019-07-24       Impact factor: 7.561

5.  Paroxetine ameliorates prodromal emotional dysfunction and late-onset memory deficit in Alzheimer's disease mice.

Authors:  Peng-Hui Ai; Si Chen; Xian-Dong Liu; Xiao-Na Zhu; Yuan-Bo Pan; Dong-Fu Feng; Shengdi Chen; Nan-Jie Xu; Suya Sun
Journal:  Transl Neurodegener       Date:  2020-05-12       Impact factor: 8.014

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.